

# Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients

Ben W. Mol, M.D., Ph.D.,<sup>a</sup> Patrick M. Bossuyt, Ph.D.,<sup>b</sup> Sesh K. Sunkara, M.D.,<sup>c</sup> Juan A. Garcia Velasco, M.D., Ph.D.,<sup>d</sup> Christos Venetis, M.D., Ph.D.,<sup>e</sup> Denny Sakkas, Ph.D.,<sup>f</sup> Kersti Lundin, Ph.D.,<sup>g</sup> Carlos Simón, M.D., Ph.D.,<sup>h</sup> Hugh S. Taylor, M.D.,<sup>i</sup> Robert Wan, Ph.D.,<sup>j</sup> Salvatore Longobardi, M.D., Ph.D.,<sup>k</sup> Evelyn Cottell, Ph.D.,<sup>k</sup> and Thomas D'Hooghe, M.D., Ph.D.<sup>k,l,m</sup>

<sup>a</sup> Monash University, Clayton, Victoria, Australia; <sup>b</sup> University of Amsterdam, Amsterdam, the Netherlands; <sup>c</sup> Queen's Hospital, Barking, Havering and Redbridge University Hospitals, Essex, United Kingdom; <sup>d</sup> IVI RMA Madrid and Rey Juan Carlos University, Madrid, Spain; <sup>e</sup> University of New South Wales, Sydney, New South Wales, Australia; <sup>f</sup> Boston IVF, Waltham, Massachusetts; <sup>g</sup> Sahlgrenska University Hospital, Goteborg, Sweden; <sup>h</sup> Igenomix, Valencia University, Valencia, Spain; <sup>i</sup> Yale University Medical School, New Haven, Connecticut; <sup>j</sup> EMD Serono, Billerica, Massachusetts; <sup>k</sup> Global Medical Affairs Fertility, Research and Development, Merck KGaA, Darmstadt, Germany; <sup>l</sup> Research Group Reproductive Medicine, Department of Development and Regeneration, Organ Systems, Group Biomedical Sciences, KU Leuven (University of Leuven), Leuven, Belgium; and <sup>m</sup> Department of Obstetrics and Gynecology, Yale University, New Haven, Connecticut

Although most medical treatments are designed for the average patient with a one-size-fits-all-approach, they may not benefit all. Better understanding of the function of genes, proteins, and metabolite, and of personal and environmental factors has led to a call for personalized medicine. Personalized reproductive medicine is still in its infancy, without clear guidance on treatment aspects that could be personalized and on trial design to evaluate personalized treatment effect and benefit-harm balance. While the rationale for a personalized approach often relies on retrospective analyses of large observational studies or real-world data, solid evidence of superiority of a personalized approach will come from randomized trials comparing outcomes and safety between a personalized and one-size-fits-all strategy. A more efficient, targeted randomized trial design may recruit only patients or couples for which the personalized approach would differ from the previous, standard approach. Multiple monocenter studies using the same study protocol (allowing future meta-analysis) might reduce the major center effect associated with multicenter studies. In certain cases, single-arm observational studies can generate the necessary evidence for a personalized approach. This review describes each of the main segments of patient care in assisted reproductive technologies treatment, addressing which aspects could be personalized, emphasizing current evidence and relevant study design. (Fertil Steril® 2018;109:968–79. Copyright ©2018 The Authors. Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)).

**Key Words:** Personalized medicine, precision medicine, trial design, ART

**Discuss:** You can discuss this article with its authors and other readers at <https://www.fertstertdialog.com/users/16110-fertility-and-sterility/posts/32491-25933>

Received March 13, 2018; revised April 23, 2018; accepted April 25, 2018.

B.W.M. is supported by a NHMRC Practitioner Fellowship (GNT1082548) and has provided consultancy for ObsEva, Merck KGaA and Guerbet. P.M.B. has nothing to disclose. S.K.S. has received grants and non-financial support from Merck and Ferring. J.A.G.V. has received grants from Merck KGaA, Merck, Sharp & Dohme and Ferring. C.V. is supported by a NHMRC Early Career Fellowship (GNT1147154) and has received personal fees and non-financial support from Merck Serono and Merck, Sharp & Dohme, and non-financial support from Ferring. D.S. has received grants from Finox Pharmaceutical, has served on a scientific advisory board for Origio, and on a speakers panel for EMD Serono. K.L. is engaged in the Scientific Educational Board for the Nordic branch of Merck-Serono and is a principle investigator in a study sponsored by Vitrolife. C.S. is scientific officer of Igenomix and has received grants from Merck, MSD and Ferring. H.S.T. has nothing to disclose. R.W. is an employee of EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany. S.L. is an employee of Merck KGaA, Darmstadt, Germany. E.C. is an employee of Merck KGaA, Darmstadt, Germany. T.D.H. is an employee of Merck KGaA, Darmstadt, Germany.

Medical writing for this article funded by Merck KGaA, Darmstadt, Germany.

Reprint requests: Thomas D'Hooghe, M.D., Ph.D., Merck KGaA, Frankfurter Str. 250, F135/002, 64293 Darmstadt, Germany (E-mail: [thomas.dhooghe@merckgroup.com](mailto:thomas.dhooghe@merckgroup.com)).

Fertility and Sterility® Vol. 109, No. 6, June 2018 0015-0282

Copyright ©2018 The Authors. Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<https://doi.org/10.1016/j.fertnstert.2018.04.037>

Most medical treatments are designed for the average patient, with a one-size-fits-all-approach. Though successful for many, this approach may not benefit all patients. An improved understanding of the function of genes, proteins, metabolites, and personal and environmental factors has led to a call for personalized medicine: a tailored approach to disease prevention and treatment that considers inter-individual differences in patients.

Despite some successes, especially in oncology, personalized medicine is

still in its infancy in reproductive medicine, possibly because treatment success (live birth) is determined by many baseline factors (in both males and females) and treatment factors (surgical, endocrinological, gamete, embryo, and uterine) (1). This review describes each of the main segments of the assisted reproductive technology (ART) patient journey, starting from ovarian stimulation and ending in live birth, addressing which aspects of patient care could be personalized, both with respect to clinical care and to future research.

## WHAT ARE THE AIMS OF FERTILITY TREATMENT?

The main aim of fertility treatment is to enable infertile couples to have a baby, and live birth is therefore the preferred primary outcome of clinical trials evaluating the effectiveness of fertility treatments (2). In reality, intermediate pregnancy outcomes (including chemical pregnancy rate, clinical pregnancy rate [CPR], and ongoing pregnancy rate [OPR]) are most commonly evaluated, with only a minority of randomized controlled trials (RCTs) in reproductive medicine reporting live birth outcomes (3). However, as these intermediate endpoints are, overall, strongly positively correlated with live birth rates (LBRs) (4, 5), a comparison between treatment groups may not be compromised. The positive association between number of oocytes, number of good quality embryos (GQE) and (cumulative) LBRs (6–8) suggests that the number of oocytes retrieved and number of embryos available may be relevant intermediate outcomes for the comparison of various ART treatments. However, it is uncertain if these outcomes are solely a consequence of the treatment, or whether they are significantly influenced by the intrinsic characteristics of the woman.

The safe delivery of a healthy baby may take several treatment cycles; therefore, the cumulative LBR per patient starting treatment is a key outcome variable. These cumulative LBRs are influenced by treatment efficacy (LBR per started treatment cycle) and intra- and inter-cycle discontinuation of treatment. While there is a lot of focus on efficacy, patient care is equally as important, as shown by the high discontinuation rates observed during ART treatment in both countries with low reimbursement rates (45% in the U.S. [9]) and countries with public reimbursement (48%–65% in the Netherlands [10], Canada [11], and Sweden [12]). Trials have shown that in systems without funding limitations, psychological stress is the most common reason for drop-out from ART treatment (13–16). A personalized management strategy, taking into account quality of care (17), targeting patient expectations, and aimed at minimizing the treatment burden and side effects as much as possible, with informed and shared decision-making between patients and healthcare professionals, could alleviate the psychological stress. Such a strategy could lead to reduced discontinuation rates and impact favorably on ART treatment outcomes by shortening the time interval between the start of treatment and conception leading to live birth. Pregnancy loss should always be incorporated in clinical decision making, owing to its psychological impact (4).

Another important consideration is safety, and particularly the potential for complications arising either directly from fertility treatment or through pregnancy or delivery. For example, while two healthy babies born from a twin pregnancy at term may be considered a good outcome for some patients (18), multiple pregnancy increases the risk of complications for both mother and babies. Achieving a singleton pregnancy should therefore be considered an important aim of treatment. Additional considerations that are relevant for patients and professionals are the time taken to achieve a live birth (19), cost and quality of care, and quality of life (20).

Time to pregnancy is of particular importance because infertility and its treatment are distressing, with couples wanting pregnancy to occur as soon as possible (19). When endpoints such as time to pregnancy are evaluated, a standard time frame should be used (e.g., time after randomization) to ensure comparability. This has not yet been adequately defined, with the latest International Committee Monitoring Assisted Reproductive Technologies (ICMART) glossary defining time to pregnancy as, “The time taken to establish a pregnancy, measured in months or in numbers of menstrual cycles” (21). We propose that time from treatment initiation (defined as the start of hormonal treatment for ovarian stimulation) to a clinical pregnancy (diagnosed by ultrasonographical visualization of one or more gestational sacs or definitive clinical signs of pregnancy [21]) that results in a live birth should be reported rather than the time to live birth, as this provides a standard starting point and will control for the gestational period.

Financial costs are also an important outcome: in a private healthcare system costs can determine whether a treatment is affordable and in a public healthcare system they can determine the overall accessibility of fertility treatment, including the number of ART cycles that are reimbursed per patient.

The individual expectations of patients should be well understood before treatment is started, to better enable personalization of the approach, and success based upon these expectations should form the basis of any treatment evaluation (22, 23).

## EVALUATING PRECISION MEDICINE DURING THE ART TREATMENT JOURNEY

### Controlled Ovarian Stimulation

The aim of controlled ovarian stimulation (COS) is to optimize the number of oocytes retrieved, so that sufficient oocytes can be safely obtained for ART treatment. Ovarian response is associated with the success of ART treatment (8, 24, 25).

**Pituitary suppression protocol.** According to three meta-analyses (26–28), gonadotropin-releasing hormone (GnRH) antagonist treatment is associated with a similar LBR compared with GnRH agonist treatment but with a lower incidence of any grade of ovarian hyperstimulation syndrome (OHSS). The reduced risk for OHSS is possibly also related to the use of a GnRH agonist instead of human chorionic gonadotropin (hCG) to trigger final oocyte maturation (29). In one meta-analysis (28)—the methodology of which has been

criticized (30)—a lower OPR was observed after antagonist treatment in the overall population but not in women with polycystic ovary syndrome (PCOS) or in women with poor ovarian response (POR). Overall, the GnRH antagonist protocol can be proposed for patients with expected normal or high ovarian response. However, there are not sufficient data to warrant abstaining from using antagonist protocols in poor responders.

#### **Gonadotropin dose: starting dose and dose adjustment.**

Ovarian reserve markers, including basal follicle-stimulating hormone (FSH), basal estradiol, inhibin B, antral follicle count (AFC), and anti-Müllerian hormone (AMH), are often used as predictors of ovarian response and for selection of the FSH dose. AFC and AMH have the highest accuracy for predicting poor and excessive response following ovarian stimulation (OS) (31). Individual patient data meta-analyses have indicated that poor response is predicted by AFC <7 and AMH <1.1 ng/mL (32–34) and hyper response by AFC >14 (35, 36) and AMH >3.5 ng/mL (37, 38).

An individualized follitropin alfa starting dose based on a nomogram (age, basal FSH, and AMH) resulted in a higher proportion of women obtaining the stated target of 8–14 oocytes compared with a fixed 150 IU dose (63% vs. 42%) (39). However, this superiority could not be confirmed for a similar reproductive outcome (proportion of women obtaining 5–12 oocytes) in another trial comparing treatment with either a fixed or an individualized gonadotropin starting dose (25). This was possibly because a mixture of follitropin alfa originator and biosimilar drugs were used in both treatment arms (and biosimilars differ from originators with respect to chemical structure, preclinical activity, and clinical effect) and/or a different nomogram was used (age, body mass index [BMI], AFC, and AMH). In non-inferiority trials evaluating individualized versus fixed starting-dose regimens for the primary outcomes of OPR (40) or number of oocytes retrieved (41), any conclusions suggesting non-inferiority (40) or lack of non-inferiority (41) can be challenged; both treatment arms were different with respect to starting dose, type of gonadotropin used (40) and dose adjustment policy (only allowed in control group) (40, 41).

However, no study, due to the small sample size, has shown that individualizing FSH starting dose based on ovarian response markers improves LBR (42). For predicted normal responders, more oocytes were retrieved with 200–225 IU FSH daily compared with 100–150 IU daily, with no significant difference observed with 225 IU compared with 300 IU daily (42). In predicted low responders, daily gonadotropin doses  $\geq$  300 IU were associated with a greater number of oocytes retrieved and significantly lower cycle cancellation due to poor response compared with doses of 150 IU, but LBRs were not improved by the higher dose (42). Similarly, the OPTIMIST study in predicted poor responders (AFC <10) showed that individualized FSH dosing (225 or 450 IU) was associated with a greater number of oocytes retrieved, a reduced incidence of cycle cancellation (4–8% vs. 30%), and a similar LBR compared with a standardized dose of 150 IU FSH (43).

In a meta-analysis (44) of three RCTs in poor responders, a higher number of oocytes retrieved but similar CPRs were observed in women after COS with a “higher” gonadotropin starting dose (450 IU [two RCTs] or 600 IU [one RCT]) compared with COS using a “lower” gonadotropin starting dose (300 IU [two RCTs] or 150 IU [one RCT]).

The data presented suggest recommended starting doses of 150–225 IU and 225–300 IU for predicted normal responders and predicted poor responders, respectively.

In expected hyper responders, lower FSH doses should be used, as they reduce the risk for OHSS without compromising success rates. The OPTIMIST study (45) in predicted hyper responders (AFC >15) showed that a 150 IU daily dose of FSH, compared with a 100 IU daily dose, significantly increased the number of oocytes retrieved and was associated with a lower first cycle cancellation rate (12% vs. 24%). However, the higher daily dose was also associated with a higher risk of mild-to-moderate OHSS (11% vs. 4%). More studies are needed to identify the optimal gonadotropin starting dose in expected high responders, taking into account not only reproductive outcomes but also the risk for OHSS and cycle cancellation.

Although dose adjustment has been allowed in most current trials, no robust trials have evaluated the effect on LBR of FSH dose adjustment during treatment (45). Individual dose adjustment after a first failed cycle and dose adjustment during OS are important areas of future research.

**Minimal/mild ovarian stimulation.** Minimal/mild OS regimens are advocated as a cost-effective alternative to conventional OS, but there is no standardized regimen for minimal stimulation. Suggested strategies include the use of anti-estrogens (e.g. clomiphene citrate) and/or aromatase inhibitors (e.g. letrozole), either alone or in combination with low-dose gonadotropins. While a recent meta-analysis observed that mild OS protocols reduced the amount of gonadotropin required and the incidence of OHSS, these protocols were also associated with a significant increase in the incidence of cycle cancellations, as well as reductions in the mean number of oocytes retrieved. Furthermore, no conclusive evidence for live-birth or pregnancy rates in both the general population and women with POR was seen (46). More evidence is needed before minimal/mild regimens are adopted into clinical practice (46); this should also take into account time to pregnancy and treatment discontinuation rate.

**Oocyte triggering.** In spontaneous ovulation cycles, FSH and luteinizing hormone (LH) show a mid-cycle surge, whereas triggering of final oocyte maturation in COS protocols traditionally relied solely on the activity of hCG to mimic the LH surge. More recently, triggering with a GnRH agonist has been employed in GnRH antagonist cycles to stimulate the LH surge. A meta-analysis of 17 trials observed that triggering with a GnRH agonist instead of hCG in fresh autologous in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles (13 trials) reduced the risk for OHSS but resulted in a much lower LBR (29). However, a more recent meta-analysis of five trials of a GnRH agonist trigger followed by luteal phase support (LPS) with LH activity versus hCG trigger

followed by standard LPS, observed that the LBR did not differ significantly between the groups. Optimization of LPS is needed to further limit OHSS in normal responder patients. In addition, no difference in the risk of OHSS was reported (OHSS occurred in 4/413 patients receiving GnRH agonist and 7/413 patients receiving hCG) (47). In donor–recipient cycles (four trials) there was no difference in LBR or OPR (29).

A meta-analysis of four trials observed a significantly higher pregnancy rate with dual trigger (hCG and GnRH agonist) compared with hCG alone (48). However, no significant differences were observed between the groups in the number of oocytes retrieved, number of mature oocytes retrieved, number of fertilized oocytes, number of good-quality embryos or implantation rate (IR) (48). Collectively, these data suggest that a GnRH agonist trigger could be useful for women undergoing freeze–all cycles, women donating oocytes, and women freezing their oocytes for fertility preservation. However, despite the reduced risk for OHSS, a few cases of severe early-onset OHSS have been reported, indicating that further fine-tuning of individualized LPS might improve results even further.

Fresh embryo transfer (ET) should not be disregarded and a GnRH agonist trigger can be used to obtain a high LBR with a low risk for OHSS. An analysis of the cost-effectiveness and impact on the patient of GnRH agonist trigger and LPS compared with hCG (the gold standard trigger) would better enable the clinical significance of both options to be judged.

## ART Laboratory Procedures

**Sperm diagnostic tests.** Compared with oocyte yield optimization and embryo selection, considerably less research effort has gone towards improving sperm yield and selection. Tests have been proposed to assess aspects including motility patterns (using computer-derived measures), chromatin errors, and apoptotic markers. However, none of these tests has been evaluated thoroughly and few are used routinely in the clinic.

A high degree of sperm DNA fragmentation is associated with poorer pregnancy rates and LBRs in couples trying to conceive naturally, by intrauterine insemination (IUI) and undergoing routine IVF, but not when ICSI was used (49–51). Meta-analysis also showed that the assay used to analyze DNA fragmentation can also have an impact on the correlations: the terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assay and the single-cell gel electrophoresis (COMET) assay have better predictive capacity than the sperm chromatin structure assay (SCSA) and sperm chromatin dispersion (SCD) test (52). A major disadvantage of DNA fragmentation testing is that the assay renders the tested sample unsuitable for clinical use. Studies are needed to confirm prospectively the hypothesis (49–51) that, in couples with a high degree of sperm DNA fragmentation, ART treatment with ICSI leads to a higher OPR and LBR than ART treatment with IVF.

When DNA damage is suspected, intra-cytoplasmic morphologically selected sperm injection (IMSI) could be used; for example, in cases of oligoasthenoteratozoospermia, with or without recurrent implantation failure after ICSI. A

meta-analysis reported improved implantation and pregnancy rates after motile sperm organelle morphology examination (MSOME) for couples with previous ICSI only or male factor infertility (53). These findings were reiterated in a systematic review of 22 trials (54), but studies reporting on LBR after MSOME followed by ICSI (IMSI) compared with ICSI alone are of poor quality (55). In summary, while the concept of advanced sperm selection shows potential for personalizing the treatment approach, there are no studies that demonstrate its clinical value.

**Type of insemination/fertilization.** The type of fertilization method is another possibility for individualization, whereby the selection criteria for IUI, IVF, or ICSI is often based on a couple's reproductive and clinical history, sperm diagnostic tests, and “post-preparation” sperm recovery and motility rates (56). Variable concentrations of viable sperm have been used as indicators for changing from IUI to IVF. One study reported that IVF should be selected if fewer than 10 million viable sperm are present in the total ejaculate (57), whereas other studies recommend this concentration in a processed sample (58). For ICSI, there is no cut-off value except sufficient viable sperm, and ICSI should be considered in cases where the sperm sample is poor (59), there is low “post-preparation” yield (often specified as a total number of sperm less than 1 million), previous fertilization failure (56) or in cases of surgically retrieved sperm (60).

Regarding implantation, a large data analysis showed that, compared with conventional IVF, ICSI was not associated with improved LBRs per transfer, irrespective of the presence of a diagnosis of male factor infertility (61). This finding was also supported by an RCT in couples with non-male factor infertility (62). However, a meta-analysis of studies where sibling oocytes were split between IVF and ICSI suggested that ICSI might increase fertilization rates and decrease risk of total failure to fertilize in couples with well-defined unexplained infertility (63), although this has not been evaluated in a RCT.

**Embryo culture, selection, and day of transfer.** Since only a limited number of fertilized oocytes/cleavage stage embryos will become good quality blastocysts on day 5 (56, 64), the number of retrieved oocytes, 2PN oocytes and/or the number of good GQE on day 2/3 can be used to individualize the selection of the day of transfer (65). However, it is well known that a proportion of non-GQE at day 2/3 will become good quality blastocysts (64).

Continuous embryo monitoring (CEM) systems enabled by time-lapse technology (TLT) hold promise to improve ART (66, 67). Such technology confers several practical benefits to the IVF laboratory (68) and enables the identification of abnormal embryo developments, including direct or reverse cleavage, which have been shown to be associated with reduced IR in retrospective studies (69, 70). However, its potential to improve embryo selection and therefore clinical outcomes is still under debate.

Recent studies have shown that fresh and frozen embryo transfer (FET) result in similar LBR, opening the way to single embryo transfer (SET) during both fresh and frozen cycles (71, 72). Assessment of embryo quality to identify the embryo



with the highest implantation potential is especially relevant for SET, as appropriate embryo selection may reduce the time to pregnancy and live birth by improving implantation rate and reducing early pregnancy loss.

**Pre-implantation genetic testing for aneuploidy.** As over half of the embryos produced by IVF are aneuploid, preimplantation genetic testing for aneuploidy (PGT-A) may identify embryos with optimal implantation potential, reduce the number of ET, and time to pregnancy in ART (73–75). Clinical outcomes are calculated as sustained implantation, referring to the number of fetal sacs over 12 or 20 weeks of gestation, and as pregnancy rates per transfer, per started cycle or per patient (76).

Mosaicism originates from the first embryo cleavage and can be identified by a trophectoderm biopsy analyzing several cells. However, it is challenging to calculate the real incidence of mosaicism in preimplantation embryos because of technical limitations (77, 78). It is important to note that the true incidence of mosaicism that could impact the accuracy of the diagnosis should not be higher than 6% (79) and the clinically recognizable error rate after PGT-A is low (80). More recently, several studies have proposed the possibility of transferring some types of mosaic embryo as they might develop into healthy euploid newborns, in particular when no euploid embryos resulted from the aneuploidy testing and low levels of mosaicism are detected in the biopsy (81–83).

In patients at advanced maternal age, overall, one or two COS cycles are needed to obtain five MII oocytes that result in at least one euploid blastocyst (76). Obviously, in low responders the number of cycles needed to obtain one euploid embryo will increase but the only other option is to transfer aneuploid embryos which are more likely to result in miscarriage or no pregnancy.

In both cleavage stage and trophectoderm biopsy, extended embryo culture is needed, and ET is performed at the blastocyst stage. This strategy could decrease the number of embryos available for transfer in patients at advanced maternal age, especially women <40 years old who are undergoing PGT-A with a small cohort of available blastocysts for biopsy. However, embryo IR with embryos not reaching the blastocyst stage are poorer. In addition, it has been recently suggested that morula can be biopsied on day 6, but these morulae are associated with higher aneuploidy rates and lower IRs compared with blastocysts (84).

A meta-analysis evaluated whether PGT-A with comprehensive chromosome screening (PGT-A-CCS) improves clinical IR and sustained IR (beyond 20 weeks) compared with routine care for embryo selection in IVF cycles. In three RCTs (n=659; all patients with normal ovarian reserve and good prognosis) at the blastocyst level, PGT-A-CCS was associated with a significantly higher clinical IR (73). However, screening with PGT-A as well as extended culture increases the risk of having no embryos for transfer, and comparative trials should be based on LBRs per started cycle. In addition, there are at present no conclusive strategies for reducing the impact of varying levels of mosaicism. Therefore, although PGT-A and selection of chromosomally euploid embryos

may reduce the miscarriage rate and shorten time to pregnancy, especially in women at advanced age (74, 75), it has not been shown to improve cumulative LBR.

**Embryo culture media.** The addition of granulocyte-macrophage colony-stimulating factor (GM-CSF), which is reported to have a protective effect on embryo stress to the embryo culture medium has been observed to have a modest positive effect on ongoing IR (OIRs) at week 7 and also on LBR, compared with control (85). Post-hoc analyses showed that GM-CSF increased OIRs in women with more than one miscarriage. However, this study had an adaptive design and the positive effect of GM-CSF was not seen when human serum albumin concentration in culture media was increased. The addition of hyaluronic acid to the culture medium showed moderate quality evidence of improvements in CPRs and LBRs in a meta-analysis of 17 trials (86). Again, further RCTs are required to assess whether these treatments are of benefit, specifically in women with unexplained miscarriage.

### Personalizing Endometrial Receptivity

Embryo implantation depends not only on the embryo but also on the endometrial window of implantation (WOI). Supraphysiological levels of hormones during COS are associated with modifications to the endometrium, including greater endometrial advancement and altered gene expression (87–89). These modifications have been suggested to have an impact on implantation and obstetric and perinatal outcomes (90). The use of freeze-all strategies has been suggested to optimize endometrial receptivity, as the transfer will happen into a more “natural” endometrium. The protocols that can be used for FET are natural cycle, modified natural cycle (ovulation is induced during a natural cycle), artificial (hormone replacement treatment [HRT]) cycle (endometrial receptivity is induced by exogenous progesterone exposure after proper priming with exogenous estradiol; GnRH agonist co-treatment may be employed to down-regulate the pituitary and prevent follicular growth) and stimulated cycles (gonadotropins are used to induce follicular development and ovulation is triggered with hCG).

A retrospective study of 1926 FET cycles performed using either an artificial or stimulated protocol, observed that artificial cycles were associated with a greater incidence of early pregnancy loss and a lower LBR compared with stimulated cycles (91). A meta-analysis that included 20 studies did not show differences in outcomes between the natural-cycle protocol, the modified natural cycle protocol or the artificial protocol (92). These data suggest that stimulated cycles might provide improved outcomes compared with natural and artificial cycles, but this should be studied by direct comparisons of the different protocols.

Another proposed method to improve endometrial receptivity is mechanical endometrial injury, also called ‘scratching’. This has been proposed to positively affect the chance of implantation after ET, but the currently available evidence (after 14 years of use) is not yet conclusive (93, 94). Ongoing large clinical trials (e.g. The SCRaTCH study) (94–96) could be

analyzed to identify any treatment selection markers that might be related to beneficial treatment outcomes.

**Identifying the window of implantation.** Failure of implantation is considered a major cause of unexplained infertility, with inadequate endometrial receptivity responsible for about two-thirds of implantation failure (97). Although most women (70%) will reach receptivity after 5 full days (120 hours; P+5) of progesterone administration in HRT cycles, or 7 days after the LH surge (168 hours; LH+7) in natural cycles, some others show a displaced (pre-receptive or post-receptive) WOI, possibly leading to recurrent implantation failure. Identification of a personalized WOI has been proposed, to synchronize ET with the optimal receptive period in a strategy known as personalized ET (pET). Endometrial transcriptomics has been suggested as a reliable and objective method for endometrial assessment according to its gene expression pattern (98, 99), leading to the development of a number of assays, including the endometrial receptivity analysis (ERA) test (100), the E-tegrity® test (101), the endometrial function test® (EFT) (102) and ReceptivaDx (103).

These tissue profiling technologies use genomic and molecular markers to evaluate the endometrium and aim to assist in optimizing treatment, including the implantation date, according to each individual's characteristics. The ERA test (<https://www.igenomix.com/provider-tests/endometrial-receptivity-test-era>) is based on next generation screening (NGS) of 236 genes identified as being involved in endometrial receptivity and has shown clinical promise in patients who repeatedly failed IVF (104, 105). The E-tegrity test is based on immunohistochemical staining of single molecules such as alpha-1, alpha-4, and beta-3 integrins (<http://www.ete-grity-test.com>) (102), the EFT is based on detection of cyclin E and cyclin-dependent kinase inhibitor p27 (<http://klimanlab.yale.edu/infertility/eft/>) (102) and endometrial BCL6 testing is proposed for ReceptivaDx (103). Endometrial receptivity has also been analyzed by immunohistochemical detection of uterine natural killer (uNK) cells. However, the prognostic value of measuring total uNK cells or CD56(+) cells in endometrial specimens remains uncertain (106).

## Embryo Transfer

The number of embryos transferred can be individualized according to the viability of the embryos, the age of the woman, and the number of previous (successful or unsuccessful) transfers. In some parts of the world, SET policies, mandating the transfer of a single embryo in the majority of cases, have successfully reduced the incidence of multiple pregnancies. However, in most countries, multiple pregnancies and births continue to be a burden, and concentrated efforts are needed to reduce this risk. Stricter SET policies for particular women, including younger women, and encouraging women with a high number of GQE towards SET and cryopreservation of the excess embryos, rather than toward multiple ET, would reduce multiple pregnancies. Good quality blastocysts obtained during the first or second cycles in women aged <36 years should be considered for SET, whereas women with a POR phenotype receiving double-embryo cleavage

stage transfer during the first cycle have only a modestly increased risk of multiple births (107).

**Freeze all strategies.** Data from two RCTs suggest that freeze-all strategies do not benefit ovulatory women (71, 72). However, these trials did not analyze whether the effectiveness of fresh or frozen transfer success varied according to baseline characteristics that are biologically linked to implantation, for example, increased progesterone concentrations at the time of hCG triggering (108) or a thin endometrium (109, 110). Indeed, observational data support a negative impact on endometrial receptivity and reproductive outcome from elevated progesterone concentrations or endometrial thickness <7 mm determined by vaginal ultrasound at the end of COS (109–113). These biomarkers should be incorporated into the design of RCTs, to evaluate if they can guide better treatment decisions.

Freeze-all strategies followed by FET could also be beneficial for ovulatory women with increased risk for OHSS, but, the cost-effectiveness of these strategies still requires evaluation. Women with PCOS may benefit from a freeze-all strategy with subsequent FET, as a higher frequency of live births and a lower frequency of pregnancy losses has been observed after FET rather than fresh transfer (114).

## Early pregnancy Management

According to most current guidelines, early pregnancy management for both natural and ART conceived pregnancies is similar, with the exception of LPS for ART pregnancies, as indicated.

**Luteal phase support.** LPS aims to compensate for the dysfunctional corpus luteum resulting from supra-physiological estradiol levels during OS suppressing LH levels.

Traditionally, patients who receive hCG to trigger oocyte maturation receive LPS (either vaginal, oral, intra-muscular, subcutaneous, or a combination) with progesterone (115). If a GnRH agonist is used as a trigger, LPS may be challenging, as there will be luteal phase insufficiency, although individual variability in steroid production has been described (116) and an ideal LPS protocol for use after GnRH trigger has not yet been defined. Patients can be treated with either intensive steroid support (high doses of oral estradiol plus intra-muscular progesterone) (117) or with low dose hCG, with the dose individualized according to the number of oocytes retrieved (118). Providing LPS via LH activity after agonist trigger is a possibility, as LH would stimulate corpora lutea to produce progesterone and other steroids. This could be done with LH directly, but this is inconvenient as it requires LH injections every 48 hours and is unlikely to be cost-effective. An alternative suggested by Humaidan et al. is to use low dose hCG (118), but this may increase the risk for OHSS after using a GnRH agonist trigger if hCG dosing is inadequate. Otherwise, all oocytes or embryos can be frozen rather than transferred, to avoid secondary OHSS if the patient gets pregnant (119). During HRT FET cycles, the luteal phase needs to be fully supported rather than supplemented, and progesterone is always needed after priming of the endometrium with estrogens.

Traditionally, patients start progesterone supplementation around the time of oocyte pick-up after hCG trigger, although starting on the day of the oocyte pick-up does not improve outcomes compared with starting 6 days later (115). Once LPS is initiated, most physicians do not monitor progesterone serum levels to titrate the dose of medication until withdrawal, rather serum levels are maintained empirically until weeks 10–12 of pregnancy. However, individual differences in absorption of the medication and patient compliance may have a clinical impact or affect the timing of treatment, meaning individualization of LPS is needed.

It is well known that vaginal progesterone and uterine levels do not correlate well with serum levels (120, 121), however, testing serum samples is the only way to monitor individual absorption into peripheral blood. Labarta et al. (122) recently demonstrated that serum levels of progesterone vary on the day of ET in women undergoing oocyte donation supplemented with micronized vaginal progesterone (400 mg twice per day), with lower pregnancy rates in patients with serum progesterone <9.2 ng/mL compared with patients with progesterone  $\geq$ 9.2 ng/mL. The WOI may also vary among women with infertility, but more research is needed to evaluate if and how serum progesterone and estradiol levels can be used to guide personalized LPS (116).

Stimulated ART cycles in which the corpus luteum is present do not need additional progesterone support after the pregnancy test, as the hCG used for triggering supports the corpus luteum for 5–7 days. Exogenous progesterone will then support the endometrium until pregnancy, after which sufficient hCG is secreted to support the pregnancy. Once hCG is detected in the blood, there is no need to maintain progesterone supplementation (123–126). In HRT FET cycles, in which there is no corpus luteum, support is required until the luteo-placental shift takes place.

### Obstetric Management

Multiple pregnancies resulting from the transfer of multiple embryos are a cause of significant adverse obstetric, fetal, perinatal and neonatal risks, but can be resolved with SET and FET. Other ART procedures, such as oocyte donation, have consistently been associated with increased risk of adverse obstetric and perinatal outcomes (127, 128). There is accumulating evidence of a higher risk of large-for-gestational-age infants and higher birth weight with FET compared with fresh ET, and fresh transfers are associated with higher risks of preterm birth, low birth weight and born small-for-gestational-age (129). When attributing risks to ART, it is important to note that the above-mentioned associations are based on observational studies, and that the pregnancy complications may be related to infertility itself and not to the treatment. Moreover, it is currently unknown whether higher surveillance is warranted with ART pregnancies. The most important group of infertile women that require special attention in pregnancy are women with PCOS who become pregnant, specifically those with the hyperandrogenic phenotype (130, 131).

### HOW CAN THE SUPERIORITY OF PERSONALIZED ART TREATMENT COMPARED WITH STANDARDIZED ART TREATMENT BE ESTABLISHED?

A number of factors may influence the outcome of treatment, including the characteristics of the couple and the treatment strategy selected, and these are also likely to interact. It may be possible to identify specific patient characteristics (e.g. female age, BMI, and duration or cause of infertility, AFC, AMH or previous ovarian response) that enable optimal treatment selection (stratified treatment). It must be emphasized, however, that when evaluating personalized medicine the prognosis should not be considered alone, and the benefit–harm balance of the treatment relative to the individual patient profile should be a major consideration for treatment selection. As such, personalized treatment requires sound evidence from strong scientific research to identify these subgroups, and to show that they genuinely differ in outcomes or benefit–harm balance.

The rationale for a personalized approach is likely to come from retrospective analyses of large observational studies or real-world data. Such analyses may suggest interaction between baseline features, markers or test results on one hand and treatment outcomes on the other. Analytical methods such as propensity scoring can be used to reduce biases to a lack of comparability in baseline and treatment characteristics between groups. Given the often small differences that are expected between personalized and standard approaches, such methods will rarely provide definitive evidence.

Thus, the value of personalized treatment selection markers should be evaluated in properly designed clinical trials. While it might seem obvious to directly compare a personalized strategy and the standard, one-size-fits-all strategy in eligible patients, one should realize that differences in outcome will only occur in those patients in whom the personalized treatment strategy differs from the one-size-fits-all strategy. As one may consider changing treatment for a subgroup only, a more efficient, targeted comparative trial would randomize only patients or couples for whom the personalized approach would differ from the previous, standard approach (132).

In certain cases, single-arm observational studies can generate the knowledge necessary for a personalized approach. This may apply if such studies can convincingly demonstrate the absence of a desired outcome after specific treatments in one subgroup, but not in others, demonstrating the absence of a treatment benefit in the former.

Despite the interest in personalized medicine, many trials do not report outcomes according to patient characteristics; rather, the focus is on reporting only the main outcomes without secondary analyses. We recommend that every RCT should include secondary analyses exploring potential treatment selection markers that identify differences in benefits across subgroups. These secondary analyses should ideally be performed with properly a priori specified hypotheses, if well-supported by prior evidence, or by original and relevant scientific rationale if prior evidence is not available. Where



possible these secondary analyses should be done with sufficient power and precision, enabling separate publication. However, it will not always be possible to provide sufficient power for secondary analyses, and in such situations exploratory secondary analyses (ideally pre-specified in study protocol, but also valuable as post hoc analyses to explain unexpected results) can still be useful to inspire further investigation and eventual confirmation in other trials, and the results could be included in a systematic review.

As ART is a stepwise process and involves a number of important treatment decisions at different time points, optimization at each time point may be expected to, but not necessarily, result in a globally optimized treatment protocol. As a result of this, it would be nearly impossible to compare the differences between all different treatment options throughout the ART treatment journey using a standard study design, owing to the unrealistic sample size and number of treatment arms required, in addition to concerns of heterogeneity.

Heterogeneity not only exists at the level of patients (age, duration and cause of infertility, ovarian reserve, number and type of previous infertility therapies, and related responses, with ovarian response to OS possibly influenced by genetic polymorphisms for LH, FSH and their receptors) (133), but can also arise from the knowledge, skill and opinions of different healthcare professionals (doctors, embryologists and nurses) in different centers. This heterogeneity is known to affect intermediate outcomes during ART treatment, such as the number of follicles observed by ultrasound scan during OS, number of oocytes retrieved after oocyte aspiration, pregnancy rate per ET, oocyte damage rate and fertilization rate after ICSI, and survival rate of cryopreserved embryos after warming/thawing. This heterogeneity in treatment effect, contributed to by both patients and healthcare professionals, results in the known center effect (134, 135), which explains why it has been impossible so far to apply models predicting pregnancy or live birth in the real world (134).

As the benefits from personalized ART treatment may be small yet clinically relevant, future multicenter trials could try to minimize the variability from center effects. Proof-of-principle evidence of the benefits of using a personalized approach can also be obtained in separate trials using the same study protocol in selected centers, with invitations based upon their established interest, commitment, trial expertise, and experience in addressing the primary study question. The selection of centers needs to be as fair as possible and efforts would be needed to ensure the selection is not influenced by economic, political and academic bias. The studies should aim to demonstrate proportional improvements in intermediate outcomes (i.e. number and quality of oocytes/embryos) and ultimately in CPRs and LBRs, as well as safety, effectiveness in terms of patient-centered outcomes, and cost-effectiveness. In addition, when personalized ART treatment is compared with standard ART treatment, these studies should be conducted in well characterized patient phenotypes. In any case, the outcomes observed in trials in selected centers should subsequently be confirmed using registries reflecting care in the real world.

Overall, this highlights that both innovative study designs and outcome assessment methods need to be further developed before a globally optimized, personalized treatment protocol can be easily produced.

## CONCLUSION

One can wonder whether any form of standardized care can exist without taking the personal characteristics, concerns and aspirations of a couple into account, and whether personalized care can exist without any form of standardization. Any form of quality care will be, to some extent, both standardized and personalized.

In this review, we have identified the most relevant and emerging areas of personalized ART and have proposed several approaches, taking the specific characteristics and aspirations of the couple into account, to develop more solid evidence of the (differential) effectiveness, safety, cost and treatment burden for the couples involved.

**Acknowledgments:** Medical writing support provided by Alexander Jones and Steven Goodrick, inScience Communications.

## REFERENCES

1. US Food and Drug Administration. Precision medicine. Available at: <https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/PrecisionMedicine-MedicalDevices/default.htm>. Accessed February 27, 2018.
2. Harbin Consensus Conference Workshop Group. Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement. *Fertil Steril* 2014;102:952–9.e15.
3. Braakhekke M, Kamphuis EI, van Rumste MM, Mol F, van der Veen F, Mol BW. How are neonatal and maternal outcomes reported in randomized controlled trials (RCTs) in reproductive medicine? *Hum Reprod* 2014;29:1211–7.
4. Clarke JF, van Rumste MM, Farquhar CM, Johnson NP, Mol BW, Herbison P. Measuring outcomes in fertility trials: can we rely on clinical pregnancy rates? *Fertil Steril* 2010;94:1647–51.
5. Braakhekke M, Kamphuis EI, Dancet EA, Mol F, van der Veen F, Mol BW. Ongoing pregnancy qualifies best as the primary outcome measure of choice in trials in reproductive medicine: an opinion paper. *Fertil Steril* 2014;101:1203–4.
6. Bosch E, Labarta E, Pellicer A. Does cumulative live birth plateau beyond a certain ovarian response? *Fertil Steril* 2017;108:943.
7. Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, et al. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? *Hum Reprod* 2016; 31:370–6.
8. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. *Hum Reprod* 2011;26:1768–74.
9. Gleicher N, Vanderlaan B, Karande V, Morris R, Nadherney K, Pratt D. Infertility treatment dropout and insurance coverage. *Obstet Gynecol* 1996;88: 289–93.
10. Land JA, Courtar DA, Evers JL. Patient dropout in an assisted reproductive technology program: implications for pregnancy rates. *Fertil Steril* 1997; 68:278–81.
11. Malcolm CE, Cumming DC. Follow-up of infertile couples who dropped out of a specialist fertility clinic. *Fertil Steril* 2004;81:269–70.
12. Olivius C, Friden B, Borg G, Bergh C. Why do couples discontinue in vitro fertilization treatment? A cohort study. *Fertil Steril* 2004;81:258–61.



13. Rajkhowa M, McConnell A, Thomas GE. Reasons for discontinuation of IVF treatment: a questionnaire study. *Hum Reprod* 2006;21:358–63.
14. Verberg MF, Eijkemans MJ, Heijnen EM, Broekmans FJ, de Klerk C, Fauser BC, et al. Why do couples drop-out from IVF treatment? A prospective cohort study. *Hum Reprod* 2008;23:2050–5.
15. Gameiro S, Boivin J, Peronace L, Verhaak CM. Why do patients discontinue fertility treatment? A systematic review of reasons and predictors of discontinuation in fertility treatment. *Hum Reprod Update* 2012;18:652–69.
16. Gameiro S, Verhaak CM, Kremer JA, Boivin J. Why we should talk about compliance with assisted reproductive technologies (ART): a systematic review and meta-analysis of ART compliance rates. *Hum Reprod Update* 2013;19:124–35.
17. Holter H, Sandin-Bojo AK, Gejvall AL, Wikland M, Wilde-Larsson B, Bergh C. Patient-centred quality of care in an IVF programme evaluated by men and women. *Hum Reprod* 2014;29:2695–703.
18. van Wely M, Twisk M, Mol BW, van der Veen F. Is twin pregnancy necessarily an adverse outcome of assisted reproductive technologies? *Hum Reprod* 2006;21:2736–8.
19. Cedars MI. Fresh versus frozen: initial transfer or cumulative cycle results: how do we interpret results and design studies? *Fertil Steril* 2016;106:251–6.
20. Domar AD. Quality of life must be taken into account when assessing the efficacy of infertility treatment. *Fertil Steril* 2018;109:71–2.
21. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The International Glossary on Infertility and Fertility Care, 2017. *Hum Reprod* 2017;32:1786–801.
22. van den Berg MMJ, Dancet EAF, Erlikh T, van der Veen F, Goddijn M, Hajenius PJ. Patient-centered early pregnancy care: a systematic review of quantitative and qualitative studies on the perspectives of women and their partners. *Hum Reprod Update* 2018;24:106–18.
23. Apers S, Dancet EAF, Aarts JWM, Kluivers KB, D'Hooghe TM, Nelen W. The association between experiences with patient-centred care and health-related quality of life in women with endometriosis. *Reprod Biomed Online* 2018;36:197–205.
24. Ji J, Liu Y, Tong XH, Luo L, Ma J, Chen Z. The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China. *Hum Reprod* 2013;28:2728–34.
25. Magnusson A, Kallen K, Thurin-Kjellberg A, Bergh C. The number of oocytes retrieved during IVF: a balance between efficacy and safety. *Hum Reprod* 2018;33:58–64.
26. Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. *Cochrane Database Syst Rev* 2016;4:CD001750.
27. Xiao JS, Su CM, Zeng XT. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis. *PLoS One* 2014;9:e106854.
28. Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. *Hum Reprod Update* 2017;23:560–79.
29. Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. *Cochrane Database Syst Rev* 2014;CD008046.
30. Kolibianakis EM, Griesinger G, Venetis CA. GnRH antagonists vs. long GnRH agonists in IVF: significant flaws in a meta-analysis lead to invalid conclusions. *Hum Reprod Update* 2017 Dec 29; DOI:10.1093/humupd/dmx038.
31. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. *Hum Reprod Update* 2006;12:685–718.
32. Broer SL, Dolleman M, van Disseldorp J, Broeze KA, Opmeer BC, Bossuyt PM, et al. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. *Fertil Steril* 2013;100:420–9.e7.
33. Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. *Hum Reprod Update* 2013;19:26–36.
34. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. *Hum Reprod* 2011;26:1616–24.
35. Ng EH, Tang OS, Ho PC. The significance of the number of antral follicles prior to stimulation in predicting ovarian responses in an IVF programme. *Hum Reprod* 2000;15:1937–42.
36. Aflatoonian A, Oskouian H, Ahmadi S, Oskouian L. Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Mullerian hormone versus small antral follicle count (2-6 mm). *J Assist Reprod Genet* 2009;26:319–25.
37. Arce JC, La Marca A, Mirner Klein B, Nyboe Andersen A, Fleming R. Anti-mullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. *Fertil Steril* 2013;99:1644–53.
38. Polyzos NP, Tournaye H, Guzman L, Camus M, Nelson SM. Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization/intracytoplasmic sperm injection. *Fertil Steril* 2013;100:430–7.
39. Allegra A, Marino A, Volpes A, Coffaro F, Scaglione P, Gullo S, et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. *Reprod Biomed Online* 2017;34:429–38.
40. Nyboe Andersen A, Nelson SM, Fauser BC, Garcia-Velasco JA, Klein BM, Arce JC. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. *Fertil Steril* 2017;107:387–96.e4.
41. Olivennes F, Trew G, Borini A, Broekmans F, Arriagada P, Warne DW, et al. Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. *Reprod Biomed Online* 2015;30:248–57.
42. Lensen SF, Wilkinson J, Leijdekkers JA, La Marca A, Mol BWJ, Marjoribanks J, et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). *Cochrane Database Syst Rev* 2018;2:CD012693.
43. van Tilborg TC, Torrance HL, Oudshoorn SC, Eijkemans MJC, Koks CAM, Verhoeve HR, et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder. *Hum Reprod* 2017;32:2496–505.
44. Youssef MA, van Wely M, Mochtar M, Fouda UM, Eldaly A, El Abidin EZ, et al. Low dosing of gonadotropins in in vitro fertilization cycles for women with poor ovarian reserve: systematic review and meta-analysis. *Fertil Steril* 2018;109:289–301.
45. Oudshoorn SC, van Tilborg TC, Eijkemans MJC, Oosterhuis GJE, Friederich J, van Hooff MHA, et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder. *Hum Reprod* 2017;32:2506–14.
46. Kamath MS, Maheshwari A, Bhattacharya S, Lor KY, Gibreel A. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation. *Cochrane Database Syst Rev* 2017;11:CD008528.
47. Haahr T, Roque M, Esteves SC, Humaidan P. GnRH agonist trigger and LH activity luteal phase support versus hCG trigger and conventional luteal phase support in fresh embryo transfer IVF/ICSI cycles—a systematic PRISMA review and meta-analysis. *Front Endocrinol (Lausanne)* 2017;8:116.
48. Ding N, Liu X, Jian Q, Liang Z, Wang F. Dual trigger of final oocyte maturation with a combination of GnRH agonist and hCG versus a hCG alone trigger in GnRH antagonist cycle for in vitro fertilization: a systematic review and meta-analysis. *Eur J Obstet Gynecol Reprod Biol* 2017;218:92–8.

49. Osman A, Alsomait H, Seshadri S, El-Toukhy T, Khalaf Y. The effect of sperm DNA fragmentation on live birth rate after IVF or ICSI: a systematic review and meta-analysis. *Reprod Biomed Online* 2015;30:120–7.
50. Evenson D, Wixon R. Meta-analysis of sperm DNA fragmentation using the sperm chromatin structure assay. *Reprod Biomed Online* 2006;12:466–72.
51. Li Z, Wang L, Cai J, Huang H. Correlation of sperm DNA damage with IVF and ICSI outcomes: a systematic review and meta-analysis. *J Assist Reprod Genet* 2006;23:367–76.
52. Cissen M, Wely MV, Scholten I, Mansell S, Bruin JP, Mol BW, et al. measuring sperm DNA fragmentation and clinical outcomes of medically assisted reproduction: a systematic review and meta-analysis. *PLoS One* 2016;11:e0165125.
53. Setti AS, Braga DP, Figueira RC, Iaconelli A Jr, Borges E. Intracytoplasmic morphologically selected sperm injection results in improved clinical outcomes in couples with previous ICSI failures or male factor infertility: a meta-analysis. *Eur J Obstet Gynecol Reprod Biol* 2014;183:96–103.
54. Boitrelle F, Guthausen B, Alter L, Bailly M, Bergere M, Wainer R, et al. High-magnification selection of spermatozoa prior to oocyte injection: confirmed and potential indications. *Reprod Biomed Online* 2014;28:6–13.
55. Teixeira DM, Barbosa MA, Ferriani RA, Navarro PA, Raine-Fenning N, Nastri CO, et al. Regular (ICSI) versus ultra-high magnification (IMSI) sperm selection for assisted reproduction. *Cochrane Database Syst Rev* 2013: CD010167.
56. ESHRE Special Interest Group of Embryology and Alpha Scientists in Reproductive Medicine. The Vienna consensus: report of an expert meeting on the development of ART laboratory performance indicators. *Reprod Biomed Online* 2017;35:494–510.
57. Dickey RP, Taylor SN, Lu PY, Sartor BM, Rye PH, Pyrzak R. Effect of diagnosis, age, sperm quality, and number of preovulatory follicles on the outcome of multiple cycles of clomiphene citrate-intrauterine insemination. *Fertil Steril* 2002;78:1088–95.
58. Miller DC, Hollenbeck BK, Smith GD, Randolph JF, Christman GM, Smith YR, et al. Processed total motile sperm count correlates with pregnancy outcome after intrauterine insemination. *Urology* 2002;60:497–501.
59. World Health Organization. WHO laboratory manual for the Examination and processing of human semen, Fifth Edition. Available at: [http://apps.who.int/iris/bitstream/10665/44261/1/9789241547789\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/44261/1/9789241547789_eng.pdf).
60. Devroey P, Van Steirteghem A. A review of ten years experience of ICSI. *Hum Reprod Update* 2004;10:19–28.
61. Boulet SL, Mehta A, Kissin DM, Warner L, Kawwass JF, Jamieson DJ. Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection. *JAMA* 2015;313:255–63.
62. Bhattacharya S, Hamilton MP, Shaaban M, Khalaf Y, Seddler M, Ghobara T, et al. Conventional in-vitro fertilisation versus intracytoplasmic sperm injection for the treatment of non-male-factor infertility: a randomised controlled trial. *Lancet* 2001;357:2075–9.
63. Johnson LN, Sasson IE, Sammel MD, Dokras A. Does intracytoplasmic sperm injection improve the fertilization rate and decrease the total fertilization failure rate in couples with well-defined unexplained infertility? A systematic review and meta-analysis. *Fertil Steril* 2013;100:704–11.
64. Guerif J, Le Gouge A, Giraudeau B, Poindron J, Bidault R, Gasnier O, et al. Limited value of morphological assessment at days 1 and 2 to predict blastocyst development potential: a prospective study based on 4042 embryos. *Hum Reprod* 2007;22:1973–81.
65. Racowsky C, Jackson KV, Cekleniak NA, Fox JH, Hornstein MD, Ginsburg ES. The number of eight-cell embryos is a key determinant for selecting day 3 or day 5 transfer. *Fertil Steril* 2000;73:558–64.
66. Pribenszky C, Nilselid AM, Montag M. Time-lapse culture with morphokinetic embryo selection improves pregnancy and live birth chances and reduces early pregnancy loss: a meta-analysis. *Reprod Biomed Online* 2017; 35:511–20.
67. Wu L, Han W, Wang J, Zhang X, Liu W, Xiong S, et al. Embryo culture using a time-lapse monitoring system improves live birth rates compared with a conventional culture system: a prospective cohort study. *Hum Fertil (Camb)* 2017:1–8.
68. Harper J, Jackson E, Sermon K, Aitken RJ, Harbottle S, Mocanu E, et al. Adjuncts in the IVF laboratory: where is the evidence for 'add-on' interventions? *Hum Reprod* 2017;32:485–91.
69. Rubio I, Kuhlmann R, Agerholm I, Kirk J, Herrero J, Escriba MJ, et al. Limited implantation success of direct-cleaved human zygotes: a time-lapse study. *Fertil Steril* 2012;98:1458–63.
70. Athayde Wirka K, Chen AA, Conaghan J, Ivani K, Gvakharia M, Behr B, et al. Atypical embryo phenotypes identified by time-lapse microscopy: high prevalence and association with embryo development. *Fertil Steril* 2014;101:1637–48.e1–5.
71. Shi Y, Sun Y, Hao C, Zhang H, Wei D, Zhang Y, et al. Transfer of Fresh versus Frozen Embryos in Ovulatory Women. *N Engl J Med* 2018;378: 126–36.
72. Vuong LN, Dang VQ, Ho TM, Huynh BG, Ha DT, Pham TD, et al. IVF Transfer of Fresh or Frozen Embryos in Women without Polycystic Ovaries. *N Engl J Med* 2018;378:137–47.
73. Dahdouh EM, Balayla J, Garcia-Velasco JA. Comprehensive chromosome screening improves embryo selection: a meta-analysis. *Fertil Steril* 2015; 104:1503–12.
74. Murphy LA, Seidler EA, Resetskova N, Penzias A, Thornton KL, Sakkasv D. Intention to treat (ITT) analysis identifying patient groups who benefit from preimplantation genetic screening (PGS). *Fertility and Sterility* 2017; 108:e281–2.
75. Maxwell SM, McCulloh DH, Lee H, Berkeley AS, Grifo J. Preimplantation genetic screening (PGS) with next generation sequencing (NGS) achieves ongoing pregnancy with fewer transfers and total miscarriages compared to non-PGS cycles. *Fertil Steril* 2017;108:e20.
76. Rubio C, Bellver J, Rodrigo L, Castillon G, Guillen A, Vidal C, et al. In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study. *Fertil Steril* 2017;107:1122–9.
77. Mamas T, Gordon A, Brown A, Harper J, Sengupta S. Detection of aneuploidy by array comparative genomic hybridization using cell lines to mimic a mosaic trophoctoderm biopsy. *Fertil Steril* 2012;97:943–7.
78. Goodrich D, Tao X, Bohrer C, Lonczak A, Xing T, Zimmerman R, et al. A randomized and blinded comparison of qPCR and Zimmmerman-based detection of aneuploidy in a cell line mixture model of blastocyst biopsy mosaicism. *J Assist Reprod Genet* 2016;33:1473–80.
79. Capalbo A, Ubaldi FM, Rienzi L, Scott R, Treff N. Detecting mosaicism in trophoctoderm biopsies: current challenges and future possibilities. *Hum Reprod* 2017;32:492–8.
80. Werner MD, Leondires MP, Schoolcraft WB, Miller BT, Copperman AB, Robins ED, et al. Clinically recognizable error rate after the transfer of comprehensive chromosomal screened euploid embryos is low. *Fertil Steril* 2014;102:1613–8.
81. Greco E, Minasi MG, Fiorentino F. Healthy Babies after Intrauterine Transfer of Mosaic Aneuploid Blastocysts. *N Engl J Med* 2015;373:2089–90.
82. Munne S, Blazek J, Large M, Martinez-Ortiz PA, Nisson H, Liu E, et al. Detailed investigation into the cytogenetic constitution and pregnancy outcome of replacing mosaic blastocysts detected with the use of high-resolution next-generation sequencing. *Fertil Steril* 2017;108:62–71.e8.
83. Spinella F, Fiorentino F, Birick A, Bono S, Ruberti A, Cotroneo E, et al. Extent of chromosomal mosaicism influences the clinical outcome of in vitro fertilization treatments. *Fertil Steril* 2018;109:77–83.
84. Irani M, Zaninovic N, Canon C, O'Neill C, Gunnala V, Zhan Q, et al. A rationale for biopsying embryos reaching the morula stage on Day 6 in women undergoing preimplantation genetic testing for aneuploidy. *Hum Reprod* 2018.
85. Ziebe S, Loft A, Povlsen BB, Erb K, Agerholm I, Aasted M, et al. A randomized clinical trial to evaluate the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) in embryo culture medium for in vitro fertilization. *Fertil Steril* 2013;99:1600–9.
86. Bontekoe S, Heineman MJ, Johnson N, Blake D. Adherence compounds in embryo transfer media for assisted reproductive technologies. *Cochrane Database Syst Rev* 2014:CD007421.
87. Ubaldi F, Bourgain C, Tournaye H, Smits J, Van Steirteghem A, Devroey P. Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval

in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase. *Fertil Steril* 1997;67:521–6.

88. Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A, et al. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. *Fertil Steril* 2002;78:1025–9.
89. Labarta E, Martinez-Conejero JA, Alama P, Horcajadas JA, Pellicer A, Simon C, et al. Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. *Hum Reprod* 2011;26:1813–25.
90. Roque M, Valle M, Kostolias A, Sampaio M, Geber S. Freeze-all cycle in reproductive medicine: current perspectives. *JBRA Assist Reprod* 2017; 21:49–53.
91. Hatoum I, Bellon L, Swierkowski N, Ouazana M, Bouba S, Fathallah K, et al. Disparities in reproductive outcomes according to the endometrial preparation protocol in frozen embryo transfer : the risk of early pregnancy loss in frozen embryo transfer cycles. *J Assist Reprod Genet* 2018;35:425–9.
92. Groenewoud ER, Cantineau AE, Kollen BJ, Macklon NS, Cohen BJ. What is the optimal means of preparing the endometrium in frozen-thawed embryo transfer cycles? A systematic review and meta-analysis. *Hum Reprod Update* 2013;19:458–70.
93. Santamaria X, Katzorke N, Simon C. Endometrial ‘scratching’: what the data show. *Curr Opin Obstet Gynecol* 2016;28:242–9.
94. van Hoogenhuijze NE, Torrance HL, Mol F, Laven JSE, Scheenjes E, Traas MAF, et al. Endometrial scratching in women with implantation failure after a first IVF/ICSI cycle; does it lead to a higher live birth rate? The SCRaTCH study: a randomized controlled trial (NTR 5342). *BMC Womens Health* 2017;17:47.
95. Goel T, Mahey R, Bhatla N, Kalaivani M, Pant S, Kriplani A. Pregnancy after endometrial scratching in infertile couples undergoing ovulation induction and intrauterine insemination cycles—a randomized controlled trial. *J Assist Reprod Genet* 2017;34:1051–8.
96. Seval MM, Sukur YE, Ozmen B, Kan O, Sonmez M, Berker B, et al. Does adding endometrial scratching to diagnostic hysteroscopy improve pregnancy rates in women with recurrent in-vitro fertilization failure? *Gynecol Endocrinol* 2016;32:957–60.
97. Simon C, Moreno C, Remohi J, Pellicer A. Cytokines and embryo implantation. *J Reprod Immunol* 1998;39:117–31.
98. Diaz-Gimeno P, Ruiz-Alonso M, Blesa D, Simon C. Transcriptomics of the human endometrium. *Int J Dev Biol* 2014;58:127–37.
99. Gomez E, Ruiz-Alonso M, Miravet J, Simon C. Human endometrial transcriptomics: implications for embryonic implantation. *Cold Spring Harb Perspect Med* 2015;5:a022996.
100. Diaz-Gimeno P, Horcajadas JA, Martinez-Conejero JA, Esteban FJ, Alama P, Pellicer A, et al. A genomic diagnostic tool for human endometrial receptivity based on the transcriptomic signature. *Fertil Steril* 2011;95:50–60, e1-15.
101. Lessey BA, Castelbaum AJ. Integrins in the endometrium of women with endometriosis. *Br J Obstet Gynaecol* 1995;102:347–8.
102. Kliman HJ, Honig S, Walls D, Luna M, McSweet JC, Copperman AB. Optimization of endometrial preparation results in a normal endometrial function test (EFT) and good reproductive outcome in donor ovum recipients. *J Assist Reprod Genet* 2006;23:299–303.
103. Almquist LD, Likes CE, Stone B, Brown KR, Savaris R, Forstein DA, et al. Endometrial BCL6 testing for the prediction of in vitro fertilization outcomes: a cohort study. *Fertil Steril* 2017;108:1063–9.
104. Giuliani E, Parkin KL, Lessey BA, Young SL, Fazolebas AT. Characterization of uterine NK cells in women with infertility or recurrent pregnancy loss and associated endometriosis. *Am J Reprod Immunol* 2014;72:262–9.
105. Ruiz-Alonso M, Galindo N, Pellicer A, Simon C. What a difference two days make: “personalized” embryo transfer (pET) paradigm: a case report and pilot study. *Hum Reprod* 2014;29:1244–7.
106. Ruiz-Alonso M, Blesa D, Diaz-Gimeno P, Gomez E, Fernandez-Sanchez M, Carranza F, et al. The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure. *Fertil Steril* 2013;100:818–24.
107. Jonsdottir I, Lundin K, Bergh C. Double embryo transfer gives good pregnancy and live birth rates in poor responders with a modest increase in multiple birth rates: results from an observational study. *Acta Obstet Gynecol Scand* 2011;90:761–6.
108. Lawrenz B, Melado L, Fatemi HM. Premature progesterone rise in ART-cycles. *Reprod Biol* 2018;18:1–4.
109. Kasius A, Smit JG, Torrance HL, Eijkemans MJ, Mol BW, Opmeer BC, et al. Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis. *Hum Reprod Update* 2014;20:530–41.
110. Ribeiro VC, Santos-Ribeiro S, De Munck N, Drakopoulos P, Polyzos NP, Schutysen V, et al. Should we continue to measure endometrial thickness in modern-day medicine? The effect on live birth rates and birth weight. *Reprod Biomed Online* 2018;36:416–26.
111. Al-Azemi M, Kyrrou D, Kolibianakis EM, Humaidan P, Van Vaerenbergh I, Devroey P, et al. Elevated progesterone during ovarian stimulation for IVF. *Reprod Biomed Online* 2012;24:381–8.
112. Kolibianakis EM, Venetis CA, Bontis J, Tarlatzis BC. Significantly lower pregnancy rates in the presence of progesterone elevation in patients treated with GnRH antagonists and gonadotrophins: a systematic review and meta-analysis. *Curr Pharm Biotechnol* 2012;13:464–70.
113. Venetis CA, Kolibianakis EM, Bosdou JK, Tarlatzis BC. Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles. *Hum Reprod Update* 2013;19:433–57.
114. Chen ZJ, Shi Y, Sun Y, Zhang B, Liang X, Cao Y, et al. Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome. *N Engl J Med* 2016; 375:523–33.
115. Connell MT, Szatkowski JM, Terry N, DeCherney AH, Propst AM, Hill MJ. Timing luteal support in assisted reproductive technology: a systematic review. *Fertil Steril* 2015;103:939–46.e3.
116. Lawrenz B, Garrido N, Samir S, Ruiz F, Melado L, Fatemi HM. Individual luteolysis pattern after GnRH-agonist trigger for final oocyte maturation. *PLoS One* 2017;12:e0176600.
117. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. *Fertil Steril* 2008; 89:84–91.
118. Humaidan P, Alsbjerg B. GnRH trigger for final oocyte maturation: is HCG trigger history? *Reprod Biomed Online* 2014;29:274–80.
119. Garcia-Velasco JA. Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. *Fertil Steril* 2012;97:527–8.
120. Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. *Obstet Gynecol* 2000;95:403–6.
121. Gibbons WE, Toner JP, Hamacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. *Fertil Steril* 1998;69:96–101.
122. Labarta E, Mariani G, Holtmann N, Celada P, Remohi J, Bosch E. Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study. *Hum Reprod* 2017;32:2437–42.
123. Aboulghar MA, Amin YM, Al-Inany HG, Aboulghar MM, Mourad LM, Serour GI, et al. Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. *Hum Reprod* 2008;23:857–62.
124. Kohls G, Ruiz F, Martinez M, Hauzman E, de la Fuente G, Pellicer A, et al. Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. *Fertil Steril* 2012;98:858–62.
125. Kyrrou D, Fatemi HM, Zepiridis L, Riva A, Papanikolaou EG, Tarlatzis BC, et al. Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. *Hum Reprod* 2011;26: 1020–4.

126. Nyboe Andersen A, Popovic-Todorovic B, Schmidt KT, Loft A, Lindhard A, Hojgaard A, et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. *Hum Reprod* 2002;17:357–61.
127. Tarlatzi TB, Imbert R, Alvaro Mercadal B, Demeestere I, Venetis CA, Englert Y, et al. Does oocyte donation compared with autologous oocyte IVF pregnancies have a higher risk of preeclampsia? *Reprod Biomed Online* 2017;34:11–8.
128. Mascarenhas M, Sunkara SK, Antonisamy B, Kamath MS. Higher risk of preterm birth and low birth weight following oocyte donation: A systematic review and meta-analysis. *Eur J Obstet Gynecol Reprod Biol* 2017; 218:60–7.
129. Maheshwari A, Pandey S, Amalraj Raja E, Shetty A, Hamilton M, Bhattacharya S. Is frozen embryo transfer better for mothers and babies? Can cumulative meta-analysis provide a definitive answer? *Hum Reprod Update* 2018;24:35–58.
130. de Wilde MA, Lamain-de Ruiters M, Veltman-Verhulst SM, Kwee A, Laven JS, Lambalk CB, et al. Increased rates of complications in singleton pregnancies of women previously diagnosed with polycystic ovary syndrome predominantly in the hyperandrogenic phenotype. *Fertil Steril* 2017;108:333–40.
131. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. *Hum Reprod Update* 2006;12:673–83.
132. Bossuyt PM, Lijmer JG, Mol BW. Randomised comparisons of medical tests: sometimes invalid, not always efficient. *Lancet* 2000;356:1844–7.
133. La Marca A, Sighinolfi G, Argento C, Grisendi V, Casarini L, Volpe A, et al. Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization. *Fertil Steril* 2013;99:970–8.e1.
134. Arvis P, Lehert P, Guivarc'h-Leveque A. Simple adaptations to the Templeton model for IVF outcome prediction make it current and clinically useful. *Hum Reprod* 2012;27:2971–8.
135. Lintsen AM, Braat DD, Habbema JD, Kremer JA, Eijkemans MJ. Can differences in IVF success rates between centres be explained by patient characteristics and sample size? *Hum Reprod* 2010;25:110–7.